Equibles does not estimate personal net worth.
Get an email with a short summary when Agios Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AGIO alertsDr. Sarah Heughan has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Brian Goff (CEO and Board Member), Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman) and 7 others.
“Turning to our pipeline on the next slide, following recent portfolio prioritization decisions, we remain focused on advancing a diversified rare hematology portfolio with opportunities across multiple stages of development.”
“And I think, Andy, here we can really look at the open-label data that we presented at EHA recently as well. So, as you know, we have very high continuation rates for people who finish the clinical trials and then go into the open-label extension.”
“Since we reported third quarter results, we have continued to make progress advancing our robust rare disease pipeline. We received the FDA approval of Agvesme for alpha and beta-thalassemia, regardless of transfusion burden, on December 23rd of last year.”
Transcript header (unverified)
Biotechnology · Healthcare
